Chief Medical Officer · Cytosorbents Corp (CTSO)

Efthymios Deliargyris

A named executive officer of Cytosorbents in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$663,455

Salary $432,586Stock awards $70,000Bonus $78,121

FY2024: $813,442

3rd of 4 named executive officers at Cytosorbents by FY2025 total.

4 named officers on file for Cytosorbents, FY2025

Efthymios Deliargyris’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cytosorbents’s whole pay program stands against its peers

  • Cytosorbents’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CTSO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 25, 2026 (DEF 14A).

Free

Get Efthymios Deliargyris’s full pay file as a PDF — free

More than this page: up to 10 years of Efthymios’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Efthymios Deliargyris compensation by year

Cytosorbents Summary Compensation Table · all 2 fiscal years held
In US dollars, as Cytosorbents reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$363,336$432,586
Bonus$162,985$78,121
Stock awards$58,255$70,000
Option awards$216,366$70,248
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$12,500$12,500
Total$813,442$663,455

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cytosorbents Corp DEF 14A filed June 25, 2026, accession 0001104659-26-077798, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cytosorbents Corp filed document, accession 0001104659-26-077798. Every figure is read from that document and cited to the page and table it appears in. Filed June 25, 2026.

$813K
$663K
FY24
FY25
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU254,334$231,444—
Option19,500—$3.53
Option43,000—$0.95
Option150,000—$1.19
Option95,000—$1.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Cytosorbents Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Cytosorbents’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Phillip ChanChief Executive Officer$808,431
Vincent CapponiPresident and Chief Operating Officer$714,372
Efthymios Deliargyris · this pageChief Medical Officer$663,455
Peter MarianiChief Financial Officer$659,872

The full Cytosorbents compensation record

free company brief

This page is one person within Cytosorbents's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cytosorbents's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Efthymios Deliargyris's compensation dossier · One-time report. No refunds.